Ovintiv Inc. (OVV)

Gross profit growth above 1.5x VET's 10.20%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.

EBIT growth above 1.5x VET's 12.87%. David Dodd would confirm if core operations or niche positioning yield superior profitability.

Operating income growth above 1.5x VET's 12.87%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.

Net income growth above 1.5x VET's 30.95%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.

EPS growth above 1.5x VET's 29.17%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.

Diluted EPS growth above 1.5x VET's 27.66%. David Dodd would see if there's a robust moat protecting these shareholder gains.

Share reduction while VET is at 1.37%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.

Reduced diluted shares while VET is at 1.20%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.

Dividend growth above 1.5x VET's 0.15%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.

OCF growth above 1.5x VET's 7.58%. David Dodd would confirm a clear edge in underlying cash generation.

Positive FCF growth while VET is negative. John Neff would see a strong competitive edge in net cash generation.

5Y revenue/share CAGR above 1.5x VET's 103.38%. David Dodd would look for consistent product or market expansions fueling outperformance.

3Y revenue/share CAGR above 1.5x VET's 71.30%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.

10Y OCF/share CAGR 1.25-1.5x VET's 341.24%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.

5Y OCF/share CAGR above 1.5x VET's 111.65%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.

3Y OCF/share CAGR 1.25-1.5x VET's 144.52%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.

5Y net income/share CAGR above 1.5x VET's 272.17%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.

Positive short-term CAGR while VET is negative. John Neff would see a clear advantage in near-term profit trajectory.

5Y equity/share CAGR above 1.5x VET's 61.77%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x VET's 26.97%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

Dividend/share CAGR of 365.25% while VET is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.

Dividend/share CAGR of 365.25% while VET is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.

Our short-term dividend growth is positive while VET cut theirs. John Neff views it as a comparative advantage in shareholder returns.

Our AR growth while VET is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.

Inventory shrinking or stable vs. VET's 117.15%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.

BV/share growth above 1.5x VET's 2.85%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

Debt shrinking faster vs. VET's 17.67%. David Dodd sees a safer balance sheet if it doesn't impair future growth.

No Data available this quarter, please select a different quarter.

Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.